ALK and non-small cell lung carcinoma: With the NSCLC harboring ALK or ROS1 rearrangements, RET-rearranged lung cancers can respond to pemetrexed-based doublet chemotherapy with an ORR of 45% and PFS of 19 months (38, 39).